Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates

Group 1: Financial Performance - Coya Therapeutics, Inc. reported a quarterly loss of $0.36 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.22, marking an earnings surprise of -63.64% [1] - The company posted revenues of $0.16 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 96.1%, compared to revenues of $3.42 million a year ago [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once [2] Group 2: Stock Performance and Outlook - Coya Therapeutics, Inc. shares have increased by approximately 7.3% since the beginning of the year, while the S&P 500 has gained 8.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.24 on revenues of $4.2 million, and for the current fiscal year, it is -$1.49 on revenues of $5.53 million [7] - The estimate revisions trend for Coya Therapeutics, Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which Coya Therapeutics, Inc. belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]